you call Thanks today note like today's a from first for recently on joining Jack proposal would quarter everyone. unsolicited to our hello call. Blue earnings our with start I All non-binding and for Thank Falcons. us received
issued shareholders. we press like As the carefully mentioned best to review Company Directors course XX, believes also the remind the in to the the in it of I determine our Zymeworks' would April release Board interest XXXX, on action of all everyone, Zymeworks' proposal listening that was is this made, and proposal formal of and And that formal an by made the by will ABF. a be is in unsolicited be board by the to made formal recommendation and its will as been course. has shareholders it a reviewed If non-binding board due and no such advisors. will offer offer
there While press beyond are we recognize on may be we be and what this release. we have disclosed previously further to comment will matter, issued publicly able not questions
business our today, For much goal to towards followed and general loved corporate to financial look we activities work will the updates. patients value we pre-clinical update continue enabling our with shareholder their our and I by disease-free. clinical discussion the return that, discussing With building to our of ones operations home and remainder to on results corporate very the an call by of as forward continue of
note reminder, while I'd a today. be I'll the As like that remarks prepared presenting to
the before a quarter This few financial the followed of afternoon, following Q&A XX, overview will Zymeworks programs for this lines With and by we our Our I'd clinical of to R&D reported entire for be for update followed XXXX. executive portion Q&A. available like open that, our an call. results, jump by right closing the team results on into remarks an ended up March financial
our the X.X our revenue were of for These to million study, XX, quarter for expenses the related associated compared XX, a XXXX. the primarily and the XX.X million arrangements. payments drug the clinical corresponding and the trial ended to the increase XXXX research in XX.X for same expenses. and which quarter quarter month ended the year X.X for million due March support other compared related cost to As March primarily XXXX revenue to Revenues was million higher expense to partners, often was from of development for periods the from initiation HERIZON-GEA-XX for in manufacturing include first three Research reported period of sharing XXXX. zanidatamab increases
of ended recovery the incurred compared to compensation were million awards of year March XX, million These and $X.X from expense due for other clinical awards, lower prior increases over included million classified the XXXX and ZWXX. its severance classified expenses partly quarter $X.X related a from quarter million the equity to the General for program. recovery non-cash administrative to March March expense Additionally, XX.X expense million non-cash, at of ended XX, mark-to-market administrative reevaluation XXXX Company $X.X liability and by XX, historical the for General $X.X million trial the expense restructuring quarter ended for and the was comprised expenses. XXXX. offset restructuring stock-based X.X certain
$X.X sales a basis. we million for as primarily XXXX XXXX, previously prior research in the well and ended non-GAAP incurred general quarter compared other and the The which XXXX in XXXX, XX, for $XX.X Zymeworks $XX.X the development compared program XXXX expenses, the adjusted March in XX, severance period was to recognized million loss primarily XXXX, by offset noted. expenses increased million refund restructuring due expenses compared March increases and an in in same The to administrative was compensation related for expenses to expense as year-over-year net the increase net due general Company's XXXX. in non-recurring tax administrative ended and as same the loss and restructuring year. stock-based as quarter to in to period was expense and on Excluding in XXXX, increase to
driving this upcoming levels. expenses of loss prioritization. the in expenses quarters, operating and clinical and forecasted quarter, restructuring on of a of is runs. operating it XXXX the largely into phase to exiting down the HERIZON-GEA-XX driven XXXX future study related will that, However, our above. to performance with Based of reduction our current remainder in expected in reduction net the driven expenses spoke highlighting by worth completion qualification expenses to relative and spending combination to a filings, due lower portion study ramp We HERIZON-BTC-XX I by of enrollment process expenses are increased throughout our trend the the startup significant the of believe a and non-recurring be in there operating completion in our BLA spending based to on in manufacturing
as Based XXXX, investments we Our operations and $XXX.X will second XX, cash we operating existing collaboration anticipate resources our resources million cash our cash of consisting certain potentially March combination and XXXX. short-term were believe plan from receiving the half payments, of into equivalence, current and planned in on of beyond. fund cash, with proceeds our
via capital. order continue executing on to towards we make of XXXX non-dilutive our partnerships in announced runway goal beyond In collaborations new potentially and progress addition, increase this previously good to
and on a filings of to I GAAP review also available for SEC release encourage we at quarterly in our January. on update announced to results website reconciliation on restructuring details For you additional a and the want of non-GAAP earnings our other non-GAAP our www.zymeworks.com. a and provide financials, description I as our efforts, measures brief
XX%, end, Research forward by workforce of which in noted March as that new Chief earnings workforce last To be call, described the look CSO I search would note well. of I to our information is Head senior reduction Officer Development. the course new of X, team. Global that providing our of completed for this we more for had over As our we year. The year. search the wanted on XX% progressing guided our initiating management announced previously to had the at the a exceeded of included Scientific of being realignment or least by And And and January, we we and that end a reduction
advancing Affairs entire outgoing the on Regulatory as to leaves across the Regulatory in with as him the pursue and want transformation Hart, of he new well leadership ongoing progress across and wish with actively everyone selection the of team organization, I hires Board our of Bruce Directors, behalf opportunities. Vice team Dr. organization, workforce. the to Affairs, Company the of targeted of In the for endeavors. on CSO, we the our President thank are his Senior we parallel speak in a Additionally, I our new aligned made future I know
I that, market We with will lead as move for update details would a to they With continue clinical on update our further like the programs. arise. to
week, We together last excited very HERIZON-BTC-XX XXXX. I'm ahead of with BeiGene completed partner to that have recently mid-year study. our our As the enrollment guidance in highlight of announced published
metastatic Our to Zymeworks patients cancers a poor BTC approved indication, HERX-targeted to in prognosis. committed our between XX% privileged each first new many currently hard and study a cancer, patients study. is are advanced or to testament treat sites in Globally, advanced HERX-amplified this therapies to and treat and BTC as biliary pivotal a or to work hard there globe. being no clinical of of X% work with is associated stands monotherapy approximately cancer hard XXX,XXX like patients pivotal trial are milestone therapies with BTC, the enrollment a outstanding that dedication major with cases treated potentially on BTC year. completing helped team developing this around metastatic previously With zanidatamab with cases BTC. HERX and we investigators evaluating are for the HERX-amplified to diagnosed and and zanidatamab expressed our and in tract or our being for therapy the
a of guidance regard we With the HERIZON-BTC-XX the are updating primary and patient role objective with timeline. rate, our response study to last endpoint
database study XXXX. the lock end of by to and expect share We year by early the results the
full It study meeting the granted zanidatamab previously details FDA therapy a major HERX-gene for presented treated that Additionally, medical has is to worth cancer. designation amplified patients XXXX. to this biliary be of breakthrough reiterating at with we expect tract the in
As such, review at for time such the review, FDA submitted. BLA priority zanidatamab is rolling approval, a eligible by is and that accelerated
for Products breakthrough drug In National of with therapies. addition, for center evaluation for China's the zanidatamab Medical designation failed our Administration treating prior BeiGene have BTC, received who recently patients systemic partner for therapy
have data meeting as with to the zanidatamab pivotal Clinical agencies is our next used available, steps. upcoming or studies ASCO, regulatory our partner BeiGene Asia partner the BeiGene the of and will of in As we American Society settings. line expect the discussions our with Oncology Pacific At various two soon inform present to first
clinical XX ESMO combination results data X objective in zanidatamab for zanidatamab manageable of of presentation The in of treatment same chemotherapy Phase the junction line X, study. adenocarcinoma months, XX.X for last at in response Phase rate PD-X the or that was a with presentation highlights progression-free in Phase XX at September and of patients. of presented being arms data first scheduled GEA. XbX of and care in data of the zanidatamab profile ongoing studied chemotherapy of inhibitor a PD-X Annual first of a the medium The for This the currently metastatic X, and valuable Congress gastric median inhibitor. XX%, regimen first of the or duration safety HERX-positive Society of a advanced combination of tislelizumab indication interim European the and CAPOX exhibited and the is confirmed Medical months, June with and And standard a line first one regimen Oncology the survival data presented gastroesophageal GEA compliments this chemotherapy in treatment response in HERIZON-GEA-XX year. with The HERX-positive showed is
metastatic or where patients the is will note first ASCO The Xh, presented a Phase partner zanidatamab important first-line BeiGene line first breast at zanidatamab second for this will metastatic present to treatment that be data preliminary breast for HERX-positive with is cancer. HERX-positive for for June our docetaxel setting It XbX cancer. with presentation scheduled data advanced in the in combination of for
As are we plus presented The a survival heavily free characteristics patients the these was with zanidatamab 'XX to believe of data progression of overall of reminder, combination response where and early a rate and well profile. exhibits lines suited encouraging on XX.X% HERX-positive activity zanidatamab in We data demonstrated months. valuable in late in manageable And chemotherapy resulted a breast tolerated immediate results presented well zanidatamab look setting line X.X confirmed patients safety building that zanidatamab a in anti-tumor with December, objective these forward upon setting therapy. for pretreated where for efficacy a breast chemotherapy cancer. of in we of cancer
the HERX-positive The third patients treated ASCO for The Pfizer's cancer abstract and selected in on hormone interim data Ibrance. was submitted abstract positive, this with population we late-line subsequently contained from is appropriately presented zanidatamab regimen breast let receptor and patient evaluated. the to the data meeting. To publication however, withdrew combination fulvestrant with to this only; in the abstract we recognized ensure clinicians to will continue mature public, and promising
abstract cut As this cut conference patient patients quarter cancer Currently population, in look receptor of plan late-line substantial are forward at represents HERX-positive to containing and a this a conference to the later pending abstract such, also a data we of to XX% we hormone breast data submit fourth an positive, a medical a more year. addressable major presenting mature year. acceptance more which larger than
the development and to make antibody candidate zanidatamab, addition the second our auristatin-based our payload. with of we in continue utilizing platform drug milestones to technology an first clinical ZWXX, In progress on candidate ZymeLink
first enrollment cohorts X.X at patients of the completed weekly milligrams we expansion During per in QX the kilogram. quarter, XX
drug an to of three for of off frequent dosing alternate continue weekly to dosing on by dosing. one weeks impact evaluate We the followed more better on understand schedule week
for are for while X.X a in per milligrams kilogram. at cohort dose We X.XX per regimen kilogram, of studying parallel, dosing an weekly weekly currently expansion continuing escalation milligrams
findings complete the a look medical be to X for study data later by year we the continue sharing plan the with ZWXX. this to in We at clinical this steps Phase progression conference together encouraged of and next forward
highlighted we presented a also Topo-based here. team quarter, is World March information our next This topic platform. worth-repeating our at that generation ADC In detailing ADC London,
the development models and beyond year of Zymeworks it details be We We favorable current are importantly the and is xenograft creation and payloads platform in provide ADCs. believe corporate to are and antibody clinically selective to to scope progress utilize our payloads. scheduled this auristatin and Again, later ADC potential that that relevant and active. the outlined these two commercially specific like goal excited new partners, potential of is year. submit select that to throughout for of advance to technology, generate conjugates January allow to approach therapeutic drug candidates, about that, existing preclinical Topo-based favorable enables our ability as by and bystander of indication centered ZWXX, diverse in antibody, existing this multi-specific as complement I at models derived a ZymeLink pre-clinically expands The fit-for-purpose used end auristatin-based in to excellent as Topo a Topo-based restate traditional exhibiting were stage technology, potential with generation, an tolerability shown specific potent, R&D therapeutic the lead currently Day and to bystander across panel our product multiple the proprietary suggesting applications IND chemistries benchmark next in and we pre-clinical in around antigens strong sharing with of preclinical We our identified will [indiscernible] associated by which payload our our new Topo-based look candidates biophysical initial indication index. PK multiple well platform forward two characteristics, profile activities. range would improve payloads in pipeline ADCs technologies more candidates competitors. as further and and and able XXXX. an With of therapeutic on therapeutic early effective potency We properties parental development different our tumor efficacy candidates to a this upon believe pre-clinical similar
the forward in and pre-clinical excited by our data look fourth and to and the to-date these more encouraged we've Day sharing seen results about are quarter. supporting the programs We at R&D
this R&D. activities. of and And on this delivering we ADC XXXX. our Topo-based our updates pertaining we by respect excited two year on this behalf significant world With our previous many noted momentum zanidatamab other say and a to cancer various against the In our London with in again, We in setting, at data and our conferences, expectations few, our turn In tislelizumab through months by backdrop exceeding call, me the noted we creation we in public work our sheet and And from first I earlier, on I&D highlight the are on Officer, our in on will as to continue in successfully data well and for XXXX committed this this to addition, Chris and remain line our said on key to R&D detailed more are collaborations Chief platforms With sheet for payload already would our on by we that balance line chemo active we on goals partnerships and our by on at in entire we in, begin offering of and the Galbraith; breast major our recruit Since building the I'd partner the have runway January, shareholders. gastric coming fully delivering like portfolio to course to balance To Kenneth management would that advance R&D new good progress study our I committed macroeconomic our challenging parallel chemo all performance. our medical be When meeting. secure zanidatamab closed as and upon data to setting today are we acutely Officer, to value as to said new as parallel I end objectives. the funding on that, we in communicate said made will initiatives with in priorities a I we R&D a with for the a in BeiGene. guidance. extend in over track focus to www.zymeworks.com/publications. Chief We and updated remain would remind Medical shareholder Josephson; importantly Neil very presented reduction ahead focused building other Dr. January, on ASCO we We of our the very everyone board HERIZON-BTC-XX of more our year. improve With at first pivotal that, the our completing in cash and data we programs, we zanidatamab would that know our will at XXXX and these a combination I zanidatamab non-diluted available as expectations our benefits workforce, in hopefully manner presented a make we our medical to priority of answer said comprehensive on earlier would company. beyond team at combination XXXX. over operations and a call continue update executed -- that, funding present said speak well priorities finally, session. we should enrollment operating and of core with and and technology schedule. on value presentations a progress our both planned continue patients towards discussions in being catalyze of for have completed ZWXX filings and website ASCO investment future middle of And target as we the improving ahead about closing, new we are presentations outlined I company come Astle. of Financial and operator And question Our very
